News

Video

A Phase 0/1 ‘Trigger’ Trial of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Patients With EGFR Alterations or Fusions

Author(s):

Nader Sanai, MD

Dr. Nader Sanai presents the findings of a phase 0/1 trigger trial (NCT06072586) that evaluates the CNS penetration of BDTX-1535 in patients with recurrent high-grade gliomas and EGFR mutations.

Related Videos
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
RMC-9805
LGSOC 2024
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Related Content
Renal Cell Carcinoma | stock.adobe.com
December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

Diffuse Glioma
November 25th 2024

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

Mirdametinib in Adult and Pediatric NF1-PN | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Larotrectinib in TRK Fusion+ CNS Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 24th 2024

Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors

Tovorafenib in Pediatric BRAF-Altered R/R Low-Grade Glioma | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 23rd 2024

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma